Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Daiichi Sankyo seeks Japanese approval for Pralia in rheumatoid arthritis

Sep. 23, 2016

Regen BioPharma's NR2F6 modulators show positive preclinical results

Sep. 22, 2016

Follistatin gene therapy receives FDA orphan designation for inclusion body myositis

Sep. 21, 2016

Confirmatory phase III study of PF-06438179 meets primary endpoint

Sep. 19, 2016

Phase II study of Flex Pharma's FLX-787 in ALS begins

Sep. 14, 2016

GlaxoSmithKline submits MAA for sirukumab in rheumatoid arthritis

Sep. 13, 2016

New approval for Bristol-Myers Squibb's Orencia in Europe

Sep. 7, 2016

Reata Pharmaceuticals presents nitric oxide production inhibitors

Sep. 7, 2016

FDA awards Santhera USD 246,000 for the development of omigapil

Sep. 1, 2016

MK-8449: a second generation SYK/ZAP70 inhibitor from Merck

Sep. 1, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...